By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
A tubeless insulin pump is a wireless insulin management system that delivers continuous insulin delivery and is connected to the remote utilising Bluetooth connectivity, thereby removing the need for several daily injections. However, the expansion of the business could be significantly impacted by the high long-term costs associated with tubeless insulin pumps and strict governmental requirements.
As a result, users face serious risks that could be fatal: stopping an insulin infusion can cause hyperglycemia and ketoacidosis, while giving too much insulin can result in severe hypoglycemia. However, there is still little information on the effectiveness and safety of CSII.
The Europe tubeless insulin pump market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The first pivotal trials of Insulet Corporation’s Omnipod 5 Automated Insulin Delivery System produced encouraging results, the company reported. The world’s leading tubeless wearable mechanism that adapts insulin delivery based on glucose trends and levels is this system. This advancement allowed the business to demonstrate its strong capacity for development.
Insulet Corporation announced that its Omnipod and Omnipod DASH insulin management systems are now FDA-approved for use with Eli Lilly’s Lyumjev injectable. The company was able to offer more clinical options for diabetes patients to manage their glucose levels and reduce post-meal increases thanks to FDA approval.
A new insulin patch pump called MEDISAFE WF is now possible thanks to a collaboration between a European business and the Terumo Corporation, a manufacturer of medical devices. In order to improve the use of MEDISAFE WITH and normalise insulin pump therapy in patients’ daily lives, the agreement was meant to benefit Terumo.
